甲状腺疾病的诊治现状及进展

doi:10.3969/j.issn.1004-583X.2016.03.012

临床荟萃 ›› 2016, Vol. 31 ›› Issue (3): 282-285.doi: 10.3969/j.issn.1004-583X.2016.03.012

甲状腺疾病的诊治现状及进展

廖海鹰,朱佩玲,张凯丽,胡志刚

河北医科大学第二医院腺体外科,河北石家庄 050000

收稿日期:2015-11-25 出版日期:2016-03-05 发布日期:2016-04-18
通讯作者: 廖海鹰, Email: liaoliao000000@sina.com
作者简介:廖海鹰，籍贯台湾新竹无党派人士，主任医师、教授、硕士研究生导师，河北医科大学第二医院腺体外科主任，中国医师协会乳腺外科专业委员会委员，中国医药教育协会乳腺疾病专业委员会常委，中华医学会河北省外科分会常委，中华医学会河北省外科分会乳腺癌委员会委员，中国医师协会河北省外科分会甲状腺外科学组组长，河北省抗癌协会甲状腺癌专业委员会副主任委员，河北省抗癌协会乳腺癌专业委员会副主任委员，第十二届全国人大代表、河北省政协委员、河北省台联副会长、石家庄台联会长，参加编写的著作有：《实用临床乳腺病学》、《袖珍外科医嘱手册》、《甲状腺切除术》、《简明普通外科》等。

Current status and progress of diagnosis and treatment in thyroid disease

Liao Haiying, Zhu Peiling, Zhang Kaili, Hu Zhigang

Department of Gland Surgery, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China

Received:2015-11-25 Online:2016-03-05 Published:2016-04-18
Contact: Liao Haiying, Email: liaoliao000000@sina.com

摘要/Abstract

摘要： 甲状腺结节的检出率逐年增高,首要问题是明确及鉴别其良恶性质,相应的治疗方法也在不断规范、改进和创新。甲状腺乳头状癌发病率越来越高,手术的适应证掌握及规范化操作,纳米碳甲状旁腺负显影技术及喉返神经探测的应用成为保护甲状旁腺,减少喉返神经损伤的重点。此外一些针对晚期甲状腺癌的靶向治疗药物也在不断探索、研究。

关键词: 甲状腺肿瘤, 纳米技术, 喉返神经, 免疫毒素类

Abstract: The detection rate of thyroid nodule is increasing year by year.The first problem is to clear and identify its evil nature,and corresponding treatment methods have been standardized, improved and innovated.The incidence of papillary thyroid cancer is increasing. The indications for surgery to master standardized operation, the nano-carbon parathyroid negative imaging techniques and applications to detect recurrent laryngeal nerve injury become the focus to protect the parathyroid gland and reduce the laryngeal recurrent nerve injury. In addition, some targeted drugs treatment for advanced thyroid cancer are also continuing to explore and research.

Key words: thyroid neoplasms, nanotechnology, recurrent laryngeal nerve, immunotoxins

中图分类号:

R736.1

廖海鹰,朱佩玲,张凯丽,胡志刚. 甲状腺疾病的诊治现状及进展[J]. 临床荟萃, 2016, 31(3): 282-285.

Liao Haiying, Zhu Peiling, Zhang Kaili, Hu Zhigang. Current status and progress of diagnosis and treatment in thyroid disease[J]. Clinical Focus, 2016, 31(3): 282-285.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.03.012

https://huicui.hebmu.edu.cn/CN/Y2016/V31/I3/282

参考文献

[1] 卢珊, 马向华, 沈捷. 甲状腺结节良恶性鉴别的研究进展[J]. 医学综述, 2010, 16(6): 859-862.
[2] 钟凯. 甲状腺癌与甲状腺结节钙化的关系探讨[J]. 中国现代医生, 2012, 50(23): 38-39, 41.
[3] 周永昌, 郭万学. 超声医学[M].4版. 北京:科学技术文献出版社, 2002: 158-159.
[4] Suen KC, Quenville NF. Fine needle aspiration biopsy of the thyroid gland: a study of 304 cases[J].J Clin Pathol, 1983, 36(9): 1036-1045.
[5] 谢朝艳, 杜心芳, 顾世明, 等. 超声引导粗针活检技术在甲状腺肿块诊断中的价值[J]. 临床医学, 2007, 27(1): 8-9.
[6] Camargo RY, Tonimori EK. Usefulness of ultrasound in the diagnosis and management of well-differentiated thyroid carcinoma[J]. Arq Bras Endocrinol Metabol, 2007, 51(5): 783-792.
[7] Cashman EC, Bresnihan M, Timon C, et al. Patients’ quality of life post thyroidectomy[J]. B-ENT, 2011, 7(4): 261-265.
[8] Wilhelm SM, Mchenry CR. Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves’ disease in the United States[J]. World J Surg, 2010, 34(6): 1261-1264.
[9] Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma:a single-institution experience using aggressive multimodal therapy[J]. Thyroid, 2011, 21(1): 25-30.
[10] 何霞云.甲状腺未分化癌的综合治疗[J]. 中国实用外科杂志, 2011, 31(5): 401-404.
[11] Passler C, Scheuba C, Prager G, et al. Anaplastic (Undifferentiated) thyroid carcinoma (ATC). A retrospective analysis[J]. Langenbecks Arch Surg, 1999, 384 (3): 284-293.
[12] Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy[J]. Thyroid, 2011, 21 (1):25-30.
[13] Roche B, Larroumets G, Dejax C, et al. Epidemiology, clinical presentation, treatment and prognosis of a regional series of 26 anaplastic thyroid carcinomas (ATC). Comparison with the literature[J]. Ann Endocrinol (Paris), 2010, 71(1):38-45.
[14] Swaak-Kragten AT, de Wilt JH, Schmitz PL, et al. Multimodality treatment for anaplastic thyroid carcinoma treatment outcome in 75 patients[J]. Radiother Oncol, 2009,92(1): 100-104.
[15] Hay ID, Thompson GB, Grant CS, et al.Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940‐1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients [J]. World J Surg, 2002, 26(8): 879- 885.
[16] Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic Review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer [J].Endocrinol Metab Clin North Am, 2008, 37(2): 457- 480.
[17] Brierley J, Tsang R, Panzarella T, et al. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years[J]. Clin Endocrinol(Oxf), 2005, 63(4): 418- 427.
[18] 范西红, 贺青卿, 张小桥, 等. 全甲状腺切除术治疗甲状腺癌102 例体会[J]. 中华普通外科杂志, 2005,20(7): 452-453.
[19] Thomusch O, Machens A, Sekulla C, et al. The impat of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patients[J]. Surgery, 2003,133(2):180-185.
[20] 马峻峰, 唐波, 李铁汉. 促甲状腺激素抑制疗法在分化型甲状腺癌治疗中的作用[J]. 中国普外基础与临床杂志,2009, 16(5): 348-355.
[21] Sanders LE, Silverman M. Follicular and Hürthle cell cacinoma: predicting outcome and directing therapy[J].Surgery,1998,124 (6): 967-974.
[22] Middendorp M, Criblwald F. UP date on recent deve1opments in the therapy of diferentiated thyroid cancer[J]. Sermin Nucl Med, 2010, 40(2): 145-152.
[23] Matuszezyk A, Petersenn S, Bockiseh A, et al. Chemotherapy with doxorubicin in progressive medulary and thyroid earcinoma of the follicular epithelium[J]. Horm Metab Res, 2008, 40(3): 210-213.
[24] Ye L, Santarpia L, Gagel RF. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors[J]. Endocr Rev, 2010, 31(4): 578-599.
[25] 钱碧云,何敏,高明, 等.2002~2006年天津市甲状腺癌发病率与26年间长期趋势分析[J]. 中华普通外科杂志, 2011, 26(4):275-278.
[26] 李伟,徐亮. 纳米碳在胃癌淋巴靶向化疗中的应用研究进展[J]. 泸州医学院学报, 2009, 32(4):439-441.
[27] 姜华, 李玺, 刘仁斌, 等. 喉肌电活动实时监测喉返神经在再次甲状腺手术中的应用[J/CD]. 中华普通外科学文献: 电子版, 2014, 8(1): 4-7.
[28] Sturgeon C, Sturgeon T, Angelos P. Neuromonitoring in thyroid surgery: attitudes, usage patterns, and predictors of use among endocrine surgeons[J]. World J Surg, 2009, 33(3): 417-425.

甲状腺疾病的诊治现状及进展

Current status and progress of diagnosis and treatment in thyroid disease

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	叶丹, 章佳波, 姚玲莉, 郭宇. CyclinD1、p27表达与甲状腺微小乳头状癌中央区淋巴结转移超声特征的关系[J]. 临床荟萃, 2021, 36(3): 262-265.
[2]	唐志金, 沈华, 于海文. 血清Cla-1、MK和Gal-1水平诊断桥本甲状腺炎合并乳头状甲状腺癌的临床价值[J]. 临床荟萃, 2020, 35(3): 255-259.
[3]	杜鹃. 超声检查对甲状腺微小乳头状癌诊断价值的探讨[J]. 临床荟萃, 2019, 34(4): 343-346.
[4]	杨锦才，李莉娟，郝正栋，郭晓嘉，楚松林，张连生. 靶向免疫负调控的药物在血液肿瘤中的应用及前景[J]. 临床荟萃, 2018, 33(8): 723-727.
[5]	李新燕，李维辰，秦明银，王丽萍. 靶向药物治疗晚期胰腺癌的Meta分析[J]. 临床荟萃, 2017, 32(5): 444-448.
[6]	余倩;李小林;乔虹. 半乳糖血凝素3在乳头状甲状腺癌中的研究进展[J]. 临床荟萃, 2014, 29(12): 1435-1437.
[7]	焦传东;张雪辉. 甲状腺微小乳头状癌中央区淋巴结转移的高危因素分析[J]. 临床荟萃, 2013, 28(6): 672-674.
[8]	栾玉杰;石建平;赵梦华. 肺动脉高压靶向药物治疗研究进展[J]. 临床荟萃, 2013, 28(6): 703-706.
[9]	唐光敏. 以腹泻首发甲状腺髓样癌伴异位促肾上腺皮质激素综合征1例[J]. 临床荟萃, 2013, 28(4): 449-450.
[10]	李兰芳;任秀宝;王华庆;刘贤明. 靶向调节性T细胞治疗的研究进展[J]. 临床荟萃, 2013, 28(11): 1299-1301.
[11]	黄盈瑞;周玲玲;戈月平;梁勇. 浙江省台州市椒江区2008～2012年甲状腺癌发病情况分析[J]. 临床荟萃, 2013, 28(11): 1210-1212.
[12]	薛帅;刘嘉;陈光. 中国甲状腺癌患者PTEN蛋白表达及其意义的Meta分析[J]. 临床荟萃, 2012, 27(23): 2036-2.0382e+007.
[13]	刘伟先;赵伟珠. 基因多态性与胃癌个体化治疗的研究进展[J]. 临床荟萃, 2012, 27(17): 1549-1554.
[14]	华云旗;毋永娟;杨永岩;杨燕霞;谭亚琴;孟令茹;袁晓荣;刘丽萍;金云剑. 表皮生长因子受体突变与肿瘤标记物在晚期非小细胞肺癌靶向治疗中意义及相关性分析[J]. 临床荟萃, 2012, 27(16): 1381-1.38514e+007.
[15]	王芳. 细针穿刺细胞学在甲状腺乳头状癌术前诊断中的应用[J]. 临床荟萃, 2012, 27(11): 977-0.